Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative

Table 4 Effect of 21 days treatment with 10 mg/day NOMAC on mean metabolic parameters in OVX rats compared with intact and OVX controls

	Alkaline phosphatase (U/L)	Glucose (g/L)	Insulin (ng/mL)	Triglycerides (mmol/L)	Total cholesterol (g/L)	HDL cholesterol (g/L)
Intact control	124	1.06	0.61	0.48	0.58*	0.33
OVX control	150	1.04	0.71	0.49	0.70	0.38
NOMAC	156	1.03	0.72	0.54	0.72	0.40

ANOVA, analysis of variance; HDL, high-density lipoprotein; NOMAC, nomegestrol acetate; OVX, ovariectomized. N = 10 per group; * P<0.05 vs OVX control (ANOVA).
Female rats weighing 180 to 200 g were OVX or kept intact 1 week before treatment was started. Rats (n = 10) were orally treated with vehicle or 10 mg/kg/day of NOMAC for 3 weeks. Blood samples were collected from fasting animals from the retro-orbital venous sinus under light ether anesthesia 1 hour ±30 minutes after treatment. Plasma samples were stored at –20ºC until measuring the alkaline phosphatase, glucose, insulin, triglycerides, cholesterol, and HDL cholesterol.

ISSN: 1477-7827